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spirin Use in Chronic Heart Failure
hat Should We Recommend to the Practitioner?
arry M. Massie, MD
an Francisco, California
There has been ongoing controversy as to whether aspirin should be used in patients with
chronic heart failure (CHF). The argument for aspirin is that many patients have underlying
coronary disease, and aspirin prevents reinfarction and other vascular events. Arguments
against the routine use of aspirin are that many CHF patients do not have underlying
coronary disease, and that the benefit of aspirin lessens after the first 6 to 12 months after
infarction. Also, several analyses suggest that aspirin may actually worsen outcomes in CHF
patients, possibly because it inhibits prostaglandins, with resulting adverse hemodynamic and
renal effects. Two recent prospective randomized studies have found that aspirin is associated
with more frequent hospitalizations for worsening heart failure, although it did not have an
adverse effect on vascular events. These results suggest that aspirin should not be routinely
used in CHF patients and be avoided in those with refractory CHF, but that it may be
beneficial in patients with recent infarction or multiple vascular risk factors. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.082Cardiol 2005;46:963–6) © 2005 by the American College of Cardiology Foundation
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boronary artery disease (CAD) is the primary etiology in
he majority of patients with chronic heart failure (CHF)
ue to systolic dysfunction, and aspirin is generally recom-
ended for patients with CAD (1,2). Therefore, it would
e reasonable to expect that aspirin would be beneficial and
idely used in CHF patients with underlying CAD. In-
tead, there has been continuing controversy and confusion
s to whether aspirin is beneficial or possibly harmful in
HF patients (3). In this brief review, I will summarize the
ources of this controversy, comment on pertinent informa-
ion that has become available recently, including the study
y Masoudi et al. (4) in this issue of the Journal, and provide
y personal perspective on how aspirin should, and should
ot, be used in CHF patients.
S ASPIRIN BENEFICIAL IN CHF PATIENTS?
he argument for using aspirin in heart failure patients is its
fficacy for patients with CAD, and this is primarily based
n the 1994 Antiplatelet Trialists’ Collaboration and the
pdated 2002 Antithrombotic Trialist Collaboration meta-
nalyses (1,5). Two points relevant to the present discussion
hould be made concerning these analyses. First, although it
s very apparent that aspirin is effective in preventing
ascular death and other vascular events when administered
arly after acute coronary events, the data are more limited
nd less convincing when taken from trials in which aspirin
as initiated in patients with chronic CAD who have not
ad recent acute coronary events or symptomatic angina. As
result, the most recent American College of Chest
From the Department of Medicine and Cardiovascular Research Institute, Uni-
ersity of California, San Francisco, California; and the Cardiology Division, San
rancisco VAMC, San Francisco, California.V
Manuscript received August 2, 2004; revised manuscript received October 14,
004, accepted October 25, 2004.hysicians Consensus Conference on Antithrombotic
herapy provided only a weak recommendation for aspirin
n patients with chronic CAD (level of evidence 2C) (6).
his is the group in which CHF patients with CAD most
ommonly fall. Second, there is sparse information available
bout the numbers of heart failure patients who may have
een included and their outcomes. With regard to the
imited information that is available, patients with heart
ailure included in post-myocardial infarction (MI) trials of
spirin demonstrated, if anything, an adverse trend (7,8).
Thus, the existing antiplatelet trials and the large meta-
nalyses do not contribute specific outcome data to support
he use of aspirin in CHF patients. Nonetheless, we all must
ecognize the validity of the oft-used maxim that “the
bsence of evidence is not evidence of absence.” The
trongest argument for using aspirin in the CHF popula-
ion, or at least that subgroup of it with known CAD, is the
ecognition that these patients remain at risk for vascular
vents, and specifically for MI, which is known to have a
arkedly adverse effect on the prognosis of CHF patients
9). However, the incidence ofMI has been consistently low in
HF patients enrolled in clinical trials enrolling CHF patients
ith moderate to severe systolic dysfunction (usually 1% to 2%
er year) and substantially lower than the mortality rates in the
ame trials. Even recognizing that MI may be underdiagnosed
n heart failure patients (10), the absolute benefit of aspirin may
e low and its benefit-to-risk ratio may not be favorable if
ounterbalancing adverse effects were present.
S ASPIRIN POTENTIALLY HARMFUL IN
EART FAILURE PATIENTS?
ontroversy concerning the use of aspirin in CHF patients
egan with post-hoc analyses of the Studies Of Left
entricular Dysfunction (SOLVD). In reviewing the rela-
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Aspirin Use in Heart Failure September 20, 2005:963–6ionship of several baseline characteristics to outcomes, Pitt
nd Yusuf (11) noted a significant interaction between
ntiplatelet therapy (primarily aspirin) and enalapril effect,
n which the angiotensin-converting enzyme (ACE) inhib-
tor benefit on survival was not observed in patients receiv-
ng antiplatelet agents. A subsequent and more extensive
nalysis of the combined SOLVD treatment and prevention
rials confirmed this interaction, with enalapril treatment
educing all-cause mortality by 23% (hazard ratio 0.77, 95%
onfidence interval 0.67 to 0.87) in patients not taking
ntiplatelet agents, versus a trend toward higher mortality in
hose taking antiplatelet agents (hazard ratio 1.10, 95%
onfidence interval 0.93 to 1.30) (12). Subsequent analyses
f other long-term ACE inhibitor trials that exclusively or
referentially enrolled patients with known vascular disease
three post-MI trials and the Heart Outcomes Prevention
valuation [HOPE] as well as the SOLVD prevention
rial) also suggested lesser benefit in patients receiving
spirin (13,14). However, despite the size, extensive pro-
pective data collection, and highly significant p values of
everal of these analyses, non-randomized observational
ohort analyses have important limitations that preclude
ausal attribution (15). Furthermore, with the salient excep-
ion of the HOPE trial, patients who were taking aspirin
ad lower mortality rates than those not taking aspirin,
hether they were assigned to the active or placebo treat-
ent groups. Thus, these post-hoc analyses cannot answer
he question of whether aspirin is beneficial (or harmful) in
HF patients.
Recently, two prospective randomized studies evaluated
he effect of aspirin in well-defined CHF populations with
educed ejection fractions. Although both were limited in
ize, their methodology makes them the most rigorous
ssessment of the efficacy of aspirin in this setting. The
arfarin/Aspirin Study in Heart Failure (WASH) was a
rospective, randomized, unblinded trial comparing no
ntithrombotic therapy with aspirin 300 mg/day and war-
arin titrated to a target international normalized ratio of 2.5
onducted as a pilot study for a potential larger trial (16). A
otal of 279 CHF patients with ejection fractions 35%
ere enrolled in the United Kingdom and U.S. End points
ere adjudicated by a committee unaware of the treatment
ssignments. The primary composite end point of death,
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CAD  coronary artery disease
CHF  chronic heart failure
MI  myocardial infarction
NSAIDs  non-steroidal anti-inflammatory drugs
SOLVD  Studies Of Left Ventricular Dysfunction
WASH  Warfarin/Aspirin Study in Heart Failure
WATCH  Warfarin and Antiplatelet Therapy in
Chronic Heart Failure trialI, or stroke was experienced by similar proportions of tatients assigned to no antithrombotic therapy, aspirin, and
arfarin (26%, 32%, and 26%, respectively). A secondary
nd point, all-cause hospitalizations, was seen more fre-
uently in the aspirin patients (64%) than either no therapy
r warfarin (48% and 47%, respectively, p  0.044). This
ifference primarily reflected a higher rate of heart failure
dmissions in the aspirin group.
The Warfarin and Antiplatelet Therapy in Chronic
eart Failure (WATCH) trial was presented at the March
004 American College of Cardiology Scientific Sessions;
he WATCH trial was a prospective, randomized trial of
pen-label warfarin titrated to a target international nor-
alized ratio of 2.5 and double-blind aspirin 162 mg or
lopidogrel 75 mg, with a primary end point of death, MI,
nd stroke. The primary hypotheses were that anticoagula-
ion with warfarin would be superior to antiplatelet therapy
ith aspirin and that antiplatelet therapy with clopidogrel
ould be superior to antiplatelet therapy with aspirin (17).
he latter hypothesis was designed to determine whether
spirin itself or as a result of an interaction with ACE
nhibitors has an adverse effect in CHF. The trial was
riginally designed to enroll 4,500 patients to provide power
o test each pairwise hypothesis at an alpha of 0.017.
nfortunately, the trial was terminated prematurely because
f lagging enrollment, with a total of 1,587 patients fol-
owed for a minimum of 12 months and a mean of 23
onths. No significant differences were observed for the
rimary outcome; however, because of its early termination,
he study only retained 41% power to detect a 20% differ-
nce. Of note is that 27% fewer patients were hospitalized
or worsening heart failure in the warfarin group compared
o the aspirin group (p  0.01), with a 31% lower overall
ate of heart failure hospitalizations. The clopidogrel group
xhibited a statistically non-significant trend toward fewer
ospitalizations compared with aspirin. Thus, the findings
f the WASH and WATCH trials are quite consistent,
emonstrating that aspirin, compared to no therapy or
arfarin, was not associated with either an increase or a
eduction in death, MI, and stroke. On the other hand, both
tudies found a substantial excess of hospitalizations for
orsening heart failure, and neither study nor the two
ombined include sufficient numbers of events to exclude a
ifference in major vascular events.
S THERE A PLAUSIBLE MECHANISM FOR AN
DVERSE EFFECT OF ASPIRIN IN CHF?
t is difficult to reach definitive conclusions from observa-
ional studies, post-hoc analyses of non-randomized sub-
roups in trials designed to address other questions, and
nderpowered randomized clinical trials—which constitute
he totality of the published data examining the efficacy and
afety of aspirin in CHF patients. However, biological
lausibility can add a greater degree of credibility to these
inds of observations, and there are plausible mechanisms
hat could explain the previously summarized findings.
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September 20, 2005:963–6 Aspirin Use in Heart Failurespirin inhibits cyclooxygenase, thereby not only inhibiting
latelet thromboxane synthesis, the presumed mechanism of
ts vascular protection, but also generation of prostacyclin
nd other prostanoids in blood vessels and other organs. In
eart failure patients, prostaglandins play an important role
n counteracting excessive vasoconstriction associated with
eurohormonal activation in this syndrome (18,19). Ad-
inistration of non-steroidal anti-inflammatory drugs
NSAIDs) including aspirin, even in low doses, can cause
emodynamic deterioration and impair renal blood flow and
enal function (18,20–23). Indeed, observational studies
ave implicated NSAIDs as increasing the risk of heart
ailure by up to 10-fold in older patients with a history of
eart disease (24,25). If the effect of aspirin is primarily a
emodynamic one, this could also explain why the primary
nding in the prospective randomized trial is an increase in
pisodes of worsening heart failure with no or relatively little
hange in the incidence of death, MI, or stroke.
One of the mechanisms by which ACE inhibitors im-
rove systemic and renal hemodynamics is through in-
reased synthesis of prostaglandins (26). As a result, some of
he effects of ACE inhibitors in CHF are exquisitely
ensitive to cyclooxygenase inhibition. Thus, aspirin in
oses used for cardioprotection can abolish the vasoconstric-
ive effects of an ACE inhibitor, whereas similar effects are
ot seen when with antiplatelet agents whose actions are not
ediated by cyclooxygenase inhibition (27). These data
ave been used to support the hypothesis that there is an
nteraction between aspirin and ACE inhibitors, which
ould explain the previously cited findings from the
OLVD trial and other studies (28). However, it is likely
hat, if aspirin does play an adverse role in heart failure, it
ould not be restricted to patients taking ACE inhibitors,
lthough it might be more apparent in this group.
The stimulus for this state-of-the-art perspective was the
bservational analysis of a large cohort of CHF patients
xamining the relationship of aspirin to outcomes by Ma-
oudi et al. (4) in this issue of the Journal. These investiga-
ors used data from a national sample of Medicare benefi-
iaries who were hospitalized for a primary diagnosis with
eart failure in 1998 to 2001, which was collected as part of
quality improvement project. They restricted their study
opulation to the 24,012 discharged patients with co-
xisting CAD, because their objective was to examine
spirin use in this population and determine the relationship
etween aspirin prescription and subsequent one-year mor-
ality. Of these, 54% were prescribed aspirin at discharge.
he primary outcome variable was death at one year.
ne-year readmission rates for all causes and for heart
ailure were also examined.
Within the limitations of observational analyses, this
tudy has much to recommend. It includes a large number of
atients with a robust database that included 195 variables
ollected from medical record reviews. Appropriate statisti-
al analyses were employed, and the results are interpreted
ith reasonable caution. However, the limitations of these mypes of analyses require emphasis. The use of aspirin was
ot random, and, not surprisingly, there are major differ-
nces between patients who were and were not prescribed
spirin. As was the case in this and in the other cohort
tudies discussed earlier, those given aspirin tended to be
ealthier and have fewer comorbid conditions. To list a few,
spirin-treated patients were: slightly younger; less likely to
ave been admitted from a skilled nursing facility; and less
ikely to have concomitant atrial fibrillation, chronic lung
isease, or dementia. They were substantially more likely to be
ischarged on ACE inhibitors and beta-blockers and less likely
o be discharged on diuretics. They were also more likely to
ave been treated at a teaching hospital and by a cardiologist.
s might be expected, they were more likely to have had a
revious MI or revascularization procedure. The investigators
ttempted to minimize the impact of these imbalances using
ppropriate adjustment procedures, but such adjustments may
ot be adequate, and the pattern of differences suggests that
here are others that were not measured, which could confound
he results. The large discrepancy between the 20% lower
nadjusted mortality rate for the aspirin-treated patients
31% vs. 39% for the no-aspirin group) and the adjusted 6%
ower relative risk is indicative of the potential impact of
dditional differences that may not have been taken into
ccount. Another problem inherent in post-discharge stud-
es, and an important potential cause of confounding, is that
othing is known of their post-discharge status and man-
gement. Thus, it is uncertain whether the discharge med-
cines, including ACE inhibitors and beta-blockers or even
spirin, were continued. The inherent assumption that
uality and intensity of post-discharge care is equal in
atients treated with and without aspirin is probably not
alid, given the differences observed in-hospital.
The primary result was a slightly lower adjusted relative
isk of death associated with aspirin treatment (hazard ratio
.94, 95% confidence interval 0.89 to 0.99). Although this
gure is reassuring in that it does not show an adverse effect
f aspirin, in light of the relatively small reduction in relative
isk and the high potential for confounding, it should not be
onsidered robust evidence that aspirin is beneficial. There
ere similar proportions of the composite of death or
eadmissions for all causes and heart failure, although
nformation is not provided on heart failure outcomes
hemselves or whether there is an adverse effect in those at
ighest risk for worsening heart failure, such as those with
oderately or severely reduced ejection fraction or abnormal
enal function. Importantly, this study does not provide any
nformation about the safety or efficacy of aspirin in heart
ailure patients without coronary disease.
SPIRIN AND HEART FAILURE: WHAT ADVICE
HOULD WE GIVE TO THE PRACTITIONER?
o what should we tell the practitioner? I do not believe
here is sufficient data to make an evidenced-based recom-
endation. With that qualification, I can only present my
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Aspirin Use in Heart Failure September 20, 2005:963–6ersonal view of the data and my approach to patients. In
eviewing the totality of the data in CHF patients that I
ave touched upon, including the study by Masoudi et al.
4), I am less concerned that aspirin has an adverse effect on
ajor vascular events (death, MI, or stroke), but I am also
ot convinced that it is beneficial, even in CHF patients
ith known CAD. I strongly suspect that aspirin is associ-
ted with more frequent episodes of worsening heart failure,
ut I recognize that the evidence for this is not conclusive.
With regard to patient treatment, I will restrict my
omments to heart failure patients with reduced systolic
unction, because the data, such as they are, are primarily
erived from this group. For patients with no evidence of
oronary or other atherosclerotic vascular disease, I see no
eason to use aspirin for primary prevention and purpose-
ully avoid doing so, even in the presence of most risk
actors. My approach to patients with known vascular
isease is more individualized. I use aspirin in those with
ecent coronary events or procedures or current angina, but
ot necessarily in those with a distant history MI. Given the
otential to worsen heart failure, I use aspirin in low doses
81 mg). However, in patients with advanced or refractory
eart failure, especially if it necessitates frequent hospital
dmissions despite optimal medical therapy (and patient
dherence to it), I believe it makes sense to consider an
lternative antithrombotic agent to aspirin in patients with
nown CAD because both WASH and WATCH trial pa-
ients receiving warfarin had fewer hospitalizations for heart
ailure, and in the WATCH trial there was a similar trend for
lopidogrel that did not reach statistical significance.
Will this issue ever be resolved? Our best hope is the
ngoing Warfarin versus Aspirin in Reduced Cardiac Ejec-
ion Fraction (WARCEF) trial, sponsored by the National
nstitute of Neurological Disease and Stroke. This study is
andomizing 2,860 patients with ejection fractions 35%
ho are in sinus rhythm. The primary end point is death or
troke, but MI and hospitalization for heart failure are two
respecified secondary end points. This trial is well powered
o determine whether one of these agents should be pre-
erred in the CHF population, but it may not answer the
uestion of whether aspirin should be used.
eprint requests and correspondence: Dr. Barry M. Massie,
ardiology Division (111C), San Francisco VAMC, 4150 Clem-
nt Street, San Francisco, California 94121. E-mail: barry.
assie@med.va.gov.
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